Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
4
50%
Ph phase_2
4
50%

Phase Distribution

4

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
4(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (50.0%)
Phase 24 (50.0%)

Trials by Status

completed675%
terminated225%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

A Study of ELX-02 in Patients With Alport Syndrome

NCT05448755
completedphase_1

Phase 1 Study of ELX-02 in Healthy Adults

NCT03292302
completedphase_2

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

NCT04126473
completedphase_2

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

NCT04135495
completedphase_1

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

NCT03776539
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05448755Phase 2

A Study of ELX-02 in Patients With Alport Syndrome

Completed
NCT03292302Phase 1

Phase 1 Study of ELX-02 in Healthy Adults

Completed
NCT04126473Phase 2

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

Completed
NCT04135495Phase 2

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Completed
NCT03776539Phase 1

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

Completed
NCT03309605Phase 1

Phase 1 Study of ELX-02 in Healthy Adult Subjects

Completed
NCT04069260Phase 2

A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis

Terminated
NCT02807961Phase 1

Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8